Valcon Medical granted authorisation by The Danish Medicines Agency for activities with euphoriant substances
Danish Medicines Agency has granted Valcon Medical the necessary approval to engage in activities related to euphoriant substances marking a significant milestone for and enforces its commitment to providing safe and effective treatments to chronic patients.
COPENHAGEN, DENMARK, June 27, 2020 - Valcon Medical, a leading pharmaceutical company specialising in the manufacturing of medical cannabis extracts and standardised oils, is pleased to announce its official authorisation from The Danish Medicines Agency for its activities involving euphoriant substances. This authorisation marks a significant first milestone for Valcon Medical and enforces its commitment to providing safe and effective treatments to chronic patients.
Danish Medicines Agency, renowned for its rigorous evaluation process, has granted Valcon Medical the necessary approval to engage in activities related to euphoriant substances. This authorisation allows Valcon Medical to conduct research, develop, manufacture, and distribute pharmaceutical products containing euphoriant substances from the cannabis plant, ensuring compliance with all relevant regulations and guidelines.
Euphoriant substances, also known as psychoactive substances, have the potential to alter mood, perception, and consciousness. Valcon Medical recognises the importance of these substances in treating various medical conditions, including mental health disorders, chronic pain, and palliative care. With this authorisation, Valcon Medical aims to manufacture medical cannabis extracts and standardised oils that can improve the quality of life for patients suffering from chronic conditions.
"We are thrilled to have received authorisation from The Danish Medicines Agency for our activities involving euphoriant substances," said Pete Patterson, CEO of Valcon Medical." This approval is a testament to our dedication to medical cannabis to advancing science and providing patients with safe and effective treatments. We are committed to conducting our activities carefully, adhering to strict regulations and guidelines to ensure the highest quality and safety standards."
The Danish Medicines Agency's authorisation of Valcon Medical's activities with euphoriant substances underscores the company's commitment to compliance, patient safety, and ethical practices. Valcon Medical will continue collaboratin with healthcare professionals, regulatory authorities, and other stakeholders to ensure the responsible use and distribution of euphoriant substances.
About Valcon Medical
Valcon Medical is a leading pharmaceutical company dedicated to improving patient outcomes through innovative healthcare solutions. With a focus on research, development, manufacturing, and distribution of EU-GMP-certified medical cannabis extracts and standardised oil products, Valcon Medical strives to address unmet medical needs and enhance the quality of life for patients worldwide. The company is committed to adhering to the highest quality, safety, and ethical standards.
You might also be interested in
Valcon Medical acquires Danish cannabis distributor and re-packer ScanLeaf ApS, extends product reach and capabilities
ScanLeaf’s market penetration, along with additional licensing, further strengthens Valcon’s position in the European Medical Cannabis market. Valcon Medical are excited to announce that they have completed the acquisition of Scanleaf ApS.
Valcon Medical is proud to announce its new partnership agreement with a well reputed Polish manufacturer of medicinal cannabis
Introduction of medicinal cannabis to the Polish market requires a marketing authorisation for a pharmaceutical raw material to prepare prescription drugs in the form of non-fibrous hemp herbs, extracts, and tinctures.
Valcon Medical Granted Authorisation by The Danish Medicines Agency for Manufacturing Cannabis Bulk Extracts under the Pilot Programme
With the authorisation to manufacture cannabis bulk extracts under the pilot programme, the company will leverage its expertise to manufacture high-quality cannabis bulk extracts, ensuring strict adherence to regulations and guidelines.